First National Advisers LLC Decreases Stake in Merck & Co., Inc. (NYSE:MRK)

First National Advisers LLC reduced its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 14.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,351 shares of the company’s stock after selling 3,802 shares during the period. First National Advisers LLC’s holdings in Merck & Co., Inc. were worth $2,224,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. State Street Corp lifted its position in shares of Merck & Co., Inc. by 1.3% during the third quarter. State Street Corp now owns 119,026,412 shares of the company’s stock worth $13,606,360,000 after purchasing an additional 1,536,474 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Merck & Co., Inc. by 4.6% during the third quarter. Wellington Management Group LLP now owns 75,809,383 shares of the company’s stock worth $8,608,914,000 after purchasing an additional 3,327,404 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Merck & Co., Inc. by 3.7% during the third quarter. Geode Capital Management LLC now owns 59,155,004 shares of the company’s stock worth $6,696,060,000 after purchasing an additional 2,134,296 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Merck & Co., Inc. by 29.7% during the fourth quarter. Bank of New York Mellon Corp now owns 24,213,537 shares of the company’s stock worth $2,408,763,000 after purchasing an additional 5,550,824 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Merck & Co., Inc. by 7.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 20,125,171 shares of the company’s stock worth $2,002,052,000 after purchasing an additional 1,317,878 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Merck & Co., Inc. news, Director Inge G. Thulin bought 2,833 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, February 6th. The stock was purchased at an average cost of $88.25 per share, for a total transaction of $250,012.25. Following the completion of the acquisition, the director now owns 2,933 shares of the company’s stock, valued at approximately $258,837.25. This represents a 2,833.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Cristal N. Downing sold 2,361 shares of the firm’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $88.76, for a total transaction of $209,562.36. Following the completion of the transaction, the insider now directly owns 7,085 shares of the company’s stock, valued at $628,864.60. This represents a 24.99 % decrease in their position. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.

Merck & Co., Inc. Price Performance

NYSE MRK opened at $94.72 on Friday. Merck & Co., Inc. has a 12 month low of $81.04 and a 12 month high of $134.63. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The firm has a market capitalization of $239.27 billion, a PE ratio of 14.07, a P/E/G ratio of 0.77 and a beta of 0.35. The company’s 50 day simple moving average is $93.57 and its 200 day simple moving average is $101.88.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Tuesday, February 4th. The company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.13). The business had revenue of $15.62 billion for the quarter, compared to the consensus estimate of $15.51 billion. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The company’s quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.03 earnings per share. As a group, equities research analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. declared that its board has approved a share repurchase program on Tuesday, January 28th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the company to reacquire up to 4.1% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its stock is undervalued.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 7th. Investors of record on Monday, March 17th will be issued a dividend of $0.81 per share. This represents a $3.24 dividend on an annualized basis and a yield of 3.42%. The ex-dividend date of this dividend is Monday, March 17th. Merck & Co., Inc.’s payout ratio is 48.14%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on MRK shares. Hsbc Global Res raised shares of Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 4th. TD Securities lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $121.00 to $100.00 in a research note on Monday, February 10th. Truist Financial reiterated a “hold” rating and set a $110.00 price objective (down previously from $130.00) on shares of Merck & Co., Inc. in a research note on Wednesday, January 8th. HSBC upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $130.00 price objective on the stock in a research note on Wednesday, December 4th. Finally, Bank of America dropped their price objective on shares of Merck & Co., Inc. from $118.00 to $112.00 and set a “buy” rating on the stock in a research note on Wednesday, February 5th. Eleven investment analysts have rated the stock with a hold rating, nine have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and a consensus target price of $117.12.

Get Our Latest Stock Analysis on MRK

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Read More

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.